NexPoint Residential (NYSE:NXRT) Stock

NexPoint Residential

NexPoint Residential Trust Inc is a real estate investment trust company. Its objectives are to maximize the cash flow and value of properties owned, acquire properties with cash flow growth potential, provide quarterly cash distributions, and achieve long-term capital appreciation for stockholders. The company seeks to achieve these objectives through targeted management and a capex value-add program. It focuses on acquiring multifamily properties in markets with attractive job growth and household formation fundamentals predominantly in the Southeastern and Southwestern United States. The company generates revenue from the rental of multifamily properties.

NexPoint Residential Trust, Inc. Common Stock

NexPoint Residential Trust Inc

Goldman Sachs analyst Jordan Alliger upgrades Old Dominion Freight Line (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODFL#NASDAQ">ODFL</a>) from Neutral to Buy and raises the price target from $190 to $200.

News

Upgrades

Price Target

Analyst Ratings

ODFL

Goldman Sachs Upgrades Old Dominion Freight Line to Buy, Raises Price Target to $200

The U.S. Department of Agriculture (USDA) has discovered a major food stamp fraud and bribery scheme, misappropriating millions of taxpayer dollars. This has led to the arrest of a USDA employee and five others.
What Happened: The USDA, along with the FBI and the U.S. Attorney's Office, has indicted six individuals in connection with a bribery and fraud scheme involving the Supplemental Nutrition Assistance Program (SNAP), allegedly resulting in over $66 million in unauthorized transactions, stated a federal press release on Friday.
The defendants, namely Michael Kehoe, Mohamad Nawafleh, Omar Alrawashdeh, Gamal Obaid, Emad Alrawashdeh and Arlasa Davis, are charged with &#8220;conspiracy to steal government funds and to misappropriate U.S. Department of Agriculture benefits,&#8221; as per a press release.
&#8220;This fraud was made possible when USDA employee Arlasa Davis betrayed the public trust by selling confidential government information to the very criminals she was supposed to catch,&#8221; declared U.S. Attorney Perry Carbone.
According to the indictment, the scheme started in 2019 with the formation of a network that distributed 160 unauthorized electronic benefit transfer (EBT) cards to stores throughout New York, illegally processing more than $30 million in EBT transactions.
The group also faces accusations of submitting fraudulent USDA applications, misusing license numbers, and falsifying documents to register unauthorized stores.
SEE ALSO: <a href="https://benzinga.com/news/politics/25/06/45715447/xi-jinpings-china-dismisses-trumps-groundless-accusations-on-geneva-trade-deal-breach-vows-strong-r" target="_blank" rel="noreferrer noopener">Xi Jinping&#8217;s China Dismisses Trump&#8217;s &#8216;Groundless&#8217; Accusations On Geneva Trade Deal Breach, Vows Strong Retaliation</a>
Why It Matters: The Trump administration had been vocal about its intentions to revamp food assistance programs. In February, the new leadership at the USDA, including Kailee Buller, the chief of staff, had <a href="https://www.benzinga.com/news/25/02/43901558/snap-benefits-in-focus-trump-admin-targets-bidens-food-assistance-policies">criticized </a>the previous administration for what they termed as &#8220;financial mismanagement&#8221; of food benefits. The Trump administration had pledged to correct these issues.
On the other hand, the rollout of the Make America Healthy Again (MAHA) food box initiative had been met with <a href="https://www.benzinga.com/personal-finance/25/05/45522362/we-have-no-details-says-food-program-director-as-trumps-maha-boxes-threaten-730000-seniors-grocery-lifeline">uncertainty and criticism</a>, making it difficult for food organizations to plan ahead. The sudden changes and lack of communication from the Trump administration had also been a point of concern. 
The 2026 budget proposal aims to cut the $425 million Commodity Supplemental Food Program, replacing it with &#8220;MAHA boxes&#8221; sourced directly from U.S. farmers, a move that could affect the grocery lifeline of over 730,000 seniors.
<ul class="wp-block-list">
<li>READ MORE: <a href="https://benzinga.com/markets/economic-data/25/06/45715685/howard-lutnick-calls-1-2-trillion-trade-deficit-a-national-emergency-says-trumps-tariffs-are-not-going-away" target="_blank" rel="noreferrer noopener">Howard Lutnick Calls $1.2 Trillion Trade Deficit A &#8216;National Emergency,&#8217; Says Trump&#8217;s Tariffs Are &#8216;Not Going Away&#8217; &#8211; Benzinga</a></li>
</ul>
Image via Shutterstock
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

Markets

Trump Administration Shuts Down $66 Million Food Stamp Fraud And Bribery Scheme, Arrests USDA Employee And 5 Others

Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) co-founder Vitalik Buterin said Friday that the blockchain's base layer will be scaled tenfold in about a year.
What happened: Buterin was speaking about ecosystem developments at a fireside chat at ETHGlobal Prague 2025.
"I think we should scale L1 by about 10x over the next year and a bit based on delay," the cryptocurrency mogul stated when asked &#8220;how fast&#8221; the recently proposed changes would be implemented.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="Kartik Talwar &amp; Vitalik Buterin I Opening Ceremonies I ETHGlobal Prague 2025" width="500" height="281" src="https://www.youtube.com/embed/zlqheiMPuhE?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Once that is accomplished, Buterin stated that the team will &#8220;take a breather&#8221; and review how far they have progressed on the decentralization goals. He said that a hard fork could then be done to "tie up loose ends."
A hard fork occurs when a new blockchain version emerges that is incompatible with the original version. Networks undergo hard forks to implement necessary changes.
See Also:<a href="https://www.benzinga.com/25/04/44621245/gold-backed-cryptos-match-yellow-metals-highs-following-trumps-liberation-day-shock"> </a><a href="https://www.benzinga.com/25/05/45556899/from-amazon-to-warren-buffetts-berkshire-hathawaybitcoin-is-now-bigger-than-these-wall-street-titans">From Warren Buffett&#8217;s Berkshire Hathaway To Jeff Bezos&#8217; Amazon — Bitcoin Is Now Outshining These Wall Street Titans</a>
Why It Matters: The mainnet, or Ethereum's base layer, has been battling a sharp dip in transaction activity. According to <a href="https://etherscan.io/chart/dailyethburnt">Etherscan</a>, the number of ETH burned has plummeted from a yearly high of 4,274 in mid-January to less than 1,000 in the previous month.
Since a portion of the transaction fees is burned, the dip was indicative of fewer transactions on the chain.
Buterin&#8217;s comments <a href="https://www.benzinga.com/25/04/44893218/ethereums-vitalik-buterin-suggests-major-overhaul-to-improve-network-efficiency-as-transaction-fees-plunge-to-5-year-lows">follow his proposal</a> for a long-term solution to improve the scalability and efficiency of the network&#8217;s execution layer, i.e., Layer-2 solutions. He theorized that, in some situations, implementing the plan might result in efficiency gains of over 100x.
Price Action: At the time of writing, ETH was exchanging hands at $2,492.06, down 0.70% in the last 24 hours, according to <a href="https://pro.benzinga.com/dashboard?_gl=1&#x2A;380nj0&#x2A;_ga&#x2A;MTEyOTAyOTcxMy4xNzEzMzY0NTYy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDk4MzIzMi42LjEuMTcxNDk4OTE0Ni4wLjAuMA..">data from Benzinga Pro</a>. 
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/cryptocurrency/25/05/45611404/anthony-scaramucci-remains-firm-on-bitcoin-as-the-best-investment-idea-even-as-the-largest-crypto-hovers-around-109000">Anthony Scaramucci Remains Firm On Bitcoin As The Best Investment Idea Even As The Largest Crypto Hovers Around $109,000</a></li>
</ul>
Photo Courtesy: VPLAB On Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$ETH

Ethereum's L1 Will Be Scaled By 10x Over The Next Year, Says Vitalik Buterin

Goldman Sachs analyst Robert Cox initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Neutral rating and announces Price Target of $38.

Initiation

Goldman Sachs Initiates Coverage On Aspen Insurance Hldgs with Neutral Rating, Announces Price Target of $38

Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) experienced a decline in sales in China compared to rivals like Nio Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>), Xpeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>), Li Auto Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LI#NASDAQ">LI</a>) and BYD Co. Ltd. (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>), which posted strong growth in May.
What Happened: Li Auto experienced 17% growth in deliveries with 40,856 vehicles delivered in May, while Nio and Xpeng posted over 33,525 and 23,321 deliveries each, a report from Barron's <a href="https://www.barrons.com/articles/chinese-ev-makers-tesla-sales-4da484e4">on</a> Sunday revealed.
Meanwhile, Chinese giant BYD's BEV (Battery Electric Vehicle) sales grew 40% year-on-year, as the company delivered 204,369 EVs in May.
However, Elon Musk's EV giant recorded around 58,000 April sales in China, including exports, and the company's sales performance in the first eight weeks of Q2 2025 declined 23% YoY, as per the report.
Why It Matters: The report comes in as Tesla has experienced a growth in May as the company posted more than 11,000 registrations in China for two consecutive weeks, despite a poor start to the month with a little over 3,000 new registrations.
Despite this, Tesla's poor run continues throughout multiple markets as the EV giant reported a <a href="https://www.benzinga.com/markets/eurozone/25/05/45616006/teslas-european-woes-see-no-end-april-sales-crash-49-as-rivals-race-ahead-in-ev-market">49% drop in sales</a> in the European market during April, as BYD overtook the company for the first time.
However, <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45589714/teslas-2025-dark-chapter-over-analyst-says-ai-autonomous-to-lift-valuation-end-black-cloud-over-stock">analysts are optimistic</a> about the company owing to June 12's Robotaxi launch in Austin as well as developments in the company's FSD tech.&nbsp;
BYD, on the other hand, continues to expand its presence in the global market while it<a href="https://www.benzinga.com/news/topics/25/06/45715047/byds-aggressive-pricing-triggers-ev-rat-race-stock-tumbles-authorities-voice-concern"> faces scrutiny from Beijing</a> over the company's aggressive discount strategy that has started a price war in the Chinese domestic EV market.
Elsewhere, Li Auto recently beat analyst expectations following the company's Q1 earnings call, where CEO Li Xiang announced the company's plans to release <a href="https://www.benzinga.com/markets/asia/25/05/45691082/tesla-rival-li-auto-will-release-2-new-suvs-this-year-ceo-li-xiang-hints-at-companys-first-sedan">2 new fully-electric SUVs</a> this year.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"><img loading="lazy" decoding="async" width="1024" height="187" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025-1024x187.jpg" alt="" class="wp-image-934782" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025-1024x187.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025-300x55.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025-768x140.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025-1536x280.jpg 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02045017/TSLA-JUN-2-2025.jpg 1662w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Tesla scores well on Momentum, Growth, and Quality metrics, but offers poor Value. For more such insights, sign up for<a href="https://www.benzinga.com/premium/ideas/benzinga-edge-2#:~:text=Turn%20Market%20Chaos,when%20markets%20rebound"> Benzinga Edge</a> today!
Check out more of Benzinga&#8217;s Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/guidance/25/05/45710828/gary-black-questions-teslas-sky-high-forward-p-e-ratio-long-term-growth-rate-needed-to-justify-a-180x-p-e-would-cause-tsla-market-cap-to-be-bigger">Gary Black Questions Tesla&#8217;s Sky-High Forward P/E Ratio: &#8216;Long-Term Growth Rate Needed To Justify a 180X P/E Would Cause Tsla Market Cap To Be Bigger&#8217;</a></li>
</ul>
Photo courtesy: Shutterstock

Tech

BYDDF

BYDDY

TSLA

XPEV

Tesla's China Sales Slump While BYD And Li Auto Post Strong Gains: Report

Life360, Inc. ("Life360" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIF#NASDAQ">LIF</a>, ASX: 360))), today announced its intention to offer, subject to market and other conditions, $250 million aggregate principal amount of convertible senior notes due 2030 (the "notes") in a private offering to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). Life360 also expects to grant the initial purchasers of the notes an option to purchase, for settlement within a period of 13 days from, and including, the date the notes are first issued, up to an additional $37.5 million aggregate principal amount of notes.
Description of notes
The notes will be senior, unsecured obligations of Life360, will accrue interest payable semi-annually in arrears and will mature on June 1, 2030, unless earlier repurchased, redeemed or converted. Noteholders will have the right to convert their notes in certain circumstances and during specified periods. Life360 will settle conversions in cash or a combination of cash and shares of its common stock, at Life360's election.
The notes will be redeemable, in whole or in part (subject to certain limitations), for cash at Life360's option at any time, and from time to time, on or after June 5, 2028 and on or before the 40th scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Life360's common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date.
If certain corporate events that constitute a "fundamental change" occur, then, subject to a limited exception, noteholders may require Life360 to repurchase their notes for cash. The repurchase price will be equal to the principal amount of the notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.
The interest rate, initial conversion rate and other terms of the notes will be determined at the pricing of the offering.
Use of proceeds
Life360 intends to use a portion of the net proceeds from the offering to fund the cost of entering into the capped call transactions. Life360 intends to use the remainder of the net proceeds from the offering for general corporate purposes, which may include acquisitions or strategic investments in complementary businesses, products, services or technologies. If the initial purchasers exercise their option to purchase additional notes, then Life360 intends to use a portion of the additional net proceeds to fund the cost of entering into additional capped call transactions as described below.

Offerings

Life360 Plans $250M Convertible Notes Offering, Eyes Future Growth and Strategic Deals

BMO Capital analyst Katja Jancic upgrades Nucor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) from Market Perform to Outperform and raises the price target from $140 to $145.

BMO Capital Upgrades Nucor to Outperform, Raises Price Target to $145

BMO Capital analyst Michael Zaremski initiates coverage on Aspen Insurance Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AHL#NYSE">AHL</a>) with a Outperform rating and announces Price Target of $38.

BMO Capital Initiates Coverage On Aspen Insurance Hldgs with Outperform Rating, Announces Price Target of $38

As Donald Trump&#8216;s administration nears completion of a proposal to ease big bank rules, Wall Street&#8217;s megabanks are largely expected to cheer the lower supplementary leverage ratio (SLR), allowing them to hold fewer capital reserves against their assets.
What Happened: Analysts largely agree that the Trump administration's push to ease big bank rules, particularly the SLR, is a boon for banks and could stimulate broader economic growth.
Gennadiy Goldberg, the head of U.S. rates strategy at TD Securities, <a href="https://www.politico.com/news/2025/05/31/trump-administration-prepares-to-ease-big-bank-rules-00377347">told </a>Politico that easing capital rules for the banks will free the capital to buy more U.S. Treasuries
However, Phillip Basil, Better Markets&#8217; director of economic growth and financial stability, told Politico that lowering big banks&#8217; capital requirements heightens financial stability risks, accusing the banking industry of exploiting recent Treasury market turmoil as a pretext to push for long-sought regulatory relief.
Meanwhile, Kepp Loeffler, the administrator of the U.S. Small Business Administration, said that Small businesses &#8220;can win with a level playing field – ESPECIALLY combined with tax cuts and deregulation.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Small businesses finally have a fighter in the White House who won't keep allowing unfair trade practices to crush their industries and outsource their jobs. They know they can win with a level playing field – ESPECIALLY combined with tax cuts and deregulation. <a href="https://t.co/APEVgiLIb6">pic.twitter.com/APEVgiLIb6</a>
&mdash; Kelly Loeffler (@SBA_Kelly) <a href="https://twitter.com/SBA_Kelly/status/1927856861576831355?ref_src=twsrc%5Etfw">May 28, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
See Also:&nbsp;<a href="https://www.benzinga.com/news/politics/25/05/45691310/trump-tariff-uncertainty-enters-courts-experts-say-investors-should-expect-elevated-turbulence-amid-the-bullish-gridlock">Trump Tariff Uncertainty Enters Courts: Experts Say ‘Investors Should Expect Elevated Turbulence' Amid The Bullish ‘Gridlock'</a>
Why It Matters: Here a list of some banking stocks that investors could consider.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Stocks</td>
<td>Year-To-Date Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>Bank of America Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAC#NYSE">BAC</a>)</td>
<td>-0.36%</td>
<td>10.66%</td>
</tr>
<tr>
<td>JPMorgan Chase &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>)</td>
<td>10.00%</td>
<td>30.81%</td>
</tr>
<tr>
<td>Goldman Sachs Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>)</td>
<td>4.43%</td>
<td>31.97%</td>
</tr>
<tr>
<td>Morgan Stanley (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MS#NYSE">MS</a>)</td>
<td>2.60%</td>
<td>31.43%</td>
</tr>
<tr>
<td>Citigroup Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/C#NYSE">C</a>)</td>
<td>7.69%</td>
<td>21.64%</td>
</tr>
<tr>
<td>Wells Fargo &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WFC#NYSE">WFC</a>)</td>
<td>6.54%</td>
<td>26.02%</td>
</tr>
<tr>
<td>Fifth Third Bancorp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FITB#NASDAQ">FITB</a>)</td>
<td>-9.44%</td>
<td>3.64%</td>
</tr>
<tr>
<td>Grupo Financiero Galicia SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GGAL#NASDAQ">GGAL</a>)</td>
<td>-15.63%</td>
<td>63.06%</td>
</tr>
<tr>
<td>BancFirst Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>)</td>
<td>6.55%</td>
<td>46.67%</td>
</tr>
</tbody>
</table>
</figure>
Here are some banking exchange-traded funds to look out for.
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>ETFs</td>
<td>Year-To-Date Performance</td>
<td>One-Year Performance</td>
</tr>
<tr>
<td>Invesco KBW Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KBWB#NASDAQ">KBWB</a>)</td>
<td>0.51%</td>
<td>22.70%</td>
</tr>
<tr>
<td>SPDR S&amp;P Bank ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBE#NYSE">KBE</a>)</td>
<td>-3.11%</td>
<td>16.44%</td>
</tr>
<tr>
<td>First Trust Nasdaq Bank ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTXO#NASDAQ">FTXO</a>)</td>
<td>-1.92%</td>
<td>17.65%</td>
</tr>
<tr>
<td>Themes Global Systemically Important Banks ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GSIB#NASDAQ">GSIB</a>)</td>
<td>25.20%</td>
<td>36.01%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) and Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which track the S&amp;P 500 index and Nasdaq 100 index, respectively, fell on Friday. The SPY was down 0.11% at $589.39, while the QQQ declined 0.16% to $519.11, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a> data.
On Monday, the futures of the S&amp;P 500, Dow Jones and Nasdaq 100 indices were trading lower.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/equities/25/05/45688628/dells-ai-server-orders-hit-record-12-1-billion-in-q1-backlog-swells-to-14-4-billion-exceptionally-strong-demand">Dell's AI Server Orders Hit Record $12.1 Billion In Q1, Backlog Swells To $14.4 Billion: ‘Exceptionally Strong Demand'Jim Cramer Attributes Nvidia's Premarket Dip To ‘Meme Money' Frenzy: ‘Just Small Motivated Shareholders Knocking It Down'</a></li>
</ul>
Photo courtesy: Shutterstock

BANF

FITB

FTXO

GGAL

GSIB

KBWB

Trump Administration Set To Ease Big Bank Rules In Major Rollback Since 2008 Crisis: Here Are The Stocks And ETFs Investors Could Consider

<ul>
<li>Real-world claims studies evaluating UZEDY&#xAE; (risperidone) also show improved adherence and persistence rates, fewer inpatient, outpatient and emergency department (ED) visits versus second-generation daily oral options</li>
<li>Latest Phase 3 SOLARIS data show no suspected or confirmed PDSS events with TEV-'749 after more than 3,400 subcutaneous injections in study participants to date</li>
<li>As a leader in neuroscience, Teva is committed to researching and developing long-acting treatment options that help address unmet needs for individuals living with schizophrenia</li>
</ul>

TEVA

Reported Friday, Teva Showcases Real-World UZEDY Data Demonstrating Lower Relapse Rates, Better Adherence, And Reduced Healthcare Use Compared To Oral Antipsychotics

The FDA's approval of mNEXSPIKE is based on results from a randomized, observer-blind, active-controlled Phase 3 clinical trial (ClinicalTrials.gov Identifier: NCT05815498), which enrolled approximately 11,400 participants aged 12 years and older. The primary efficacy objective in this study was to demonstrate the non-inferior vaccine efficacy against COVID-19 starting 14 days after mNEXSPIKE compared to that after the comparator vaccine, mRNA-1273 (Spikevax&#xAE;), Moderna's original COVID-19 vaccine. Participants received either a 10 μg dose of mRNA-1283 or a 50 μg dose of mRNA-1273. mRNA-1283 showed a 9.3% higher relative vaccine efficacy (rVE) compared to mRNA-1273 in individuals aged 12 years and older, and in a descriptive sub-group analysis, a 13.5% higher rVE in adults aged 65 and older.

MRNA

Reported Saturday, mNEXSPIKE Becomes FDA-Approved: Moderna's New COVID-19 Vaccine Shows Higher Efficacy vs. Spikevax In Phase 3 Trial

<ul>
<li>26% preliminary objective response rate observed in heavily pre-treated patients with metastatic microsatellite stable colorectal cancer (MSS CRC) without liver metastases</li>
<li>Deep and durable responses ongoing for up to 37 weeks through the data cutoff, accompanied by substantial decreases in tumor biomarkers and improvements in clinical symptoms</li>
<li>MSS CRC patient with liver metastasis and previously reported confirmed partial response from Phase 1C (combination dose escalation) remains on treatment after more than 14 months</li>
<li>Combination continued to demonstrate differentiated safety and tolerability profile with low incidence of colitis and other immune-related adverse events</li>
</ul>

Reported Saturday, Xilio's Tumor-Activated Anti-CTLA-4 Vilastobart Shows 26% Objective Response Rate With Durable Responses And Low Colitis In MSS CRC Without Liver Metastases

<ul>
<li>Extended Phase 1b trial follow-up on IMA203 PRAME cell therapy in 33 heavily pretreated patients with metastatic melanoma demonstrates favorable tolerability and promising clinical activity with ongoing deep and durable objective responses up to &gt;2.5 years &nbsp;</li>
<li>IMA203 PRAME cell therapy one-time infusion in all melanoma patients shows cORR of 56%; mDOR of 12.1 months at mFU of 13.4 months; mPFS of 6.1 months; mOS of 15.9 months 
<ul>
<li>Cutaneous melanoma subgroup post-checkpoint inhibitor shows cORR of 50%, mDOR not reached at mFU of 16.7 months; mPFS of 6.0 months</li>
<li>Uveal melanoma subgroup, including tebentafusp-refractory patients shows cORR of 67%, mDOR of 11.0 months at mFU of 13.4 months; mPFS of 8.5 months &nbsp;</li>
</ul>
</li>
<li>Positive Phase 1b data and high PRAME prevalence in melanoma reinforce the basis for the ongoing SUPRAME Phase 3 trial in previously treated advanced or metastatic cutaneous melanoma, as well as the continued Phase 1b expansion in uveal melanoma &nbsp;</li>
<li>ASCO presentations further substantiate Immatics' global leadership in precision targeting of PRAME and potential of IMA203 to be the Company's first PRAME product &nbsp;</li>
</ul>

IMTX

Reported Saturday, Immatics Presents Expanded IMA203 PRAME Cell Therapy Results At ASCO: Durable Objective Responses In 91% Of Patients And Favorable Safety Profile

A new study has warned that declining childhood vaccination rates in the United States could trigger a dramatic resurgence of diseases that were eradicated years ago.
What Happened: On Sunday, former U.S. Food and Drug Administration (FDA) Commissioner Scott Gottlieb shared a study on X highlighting the consequences of America&#8217;s turn towards vaccine skepticism, and a policy framework that is increasingly enabling the same.
While sharing a study titled Modeling Reemergence of Vaccine-Eliminated Infectious Diseases Under Declining Vaccination, Gottlieb quotes from it, saying, &#8220;at current vaccination rates, measles may become endemic again.&#8221;
See Also: <a href="https://www.benzinga.com/cannabis/25/06/45715155/elizabeth-warren-calls-it-textbook-corruption-once-again-asks-for-probe-into-elon-musk-cashing-in-on-trump-tariffs">Elizabeth Warren Calls It &#8216;Textbook Corruption,&#8217; Once Again Asks For Probe Into Elon Musk &#8216;Cashing In&#8217; On Trump Tariffs</a>
He highlighted the staggering projections from the study, &#8220;51.2 [million] measles cases over a 25-year period, 9.9 [million] rubella cases, 4.3 [million] poliomyelitis cases, 197 diphtheria cases, 10.3 [million] hospitalizations, and 159,200 deaths.&#8221;
The Stanford University study&#8217;s projections are based on a scenario in which vaccine uptake drops 50%, at which point it finds that measles alone could reach endemic levels within just 5 years. 
Even at current vaccination levels, the study estimates an 83% chance of measles returning to endemicity within two decades.
The study also projects 9.9 million rubella cases, 4.3 million polio cases, and nearly 11,000 instances of congenital rubella syndrome in the event of steep declines in vaccination. The forecast includes as many as 5,400 cases of paralytic polio, a disease declared eliminated in the U.S. in 1979.
These findings come amid rising anti-vaccine sentiments in the country, alongside proposed <a href="https://www.benzinga.com/government/regulations/25/05/45688464/rfk-jr-drops-covid-vaccine-recommendation-for-healthy-kids-but-experts-warn-of-major-risks">policy rollbacks</a> on vaccine mandates. 
<figure class="wp-block-embed aligncenter is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">‘At current vaccination rates, measles may become endemic again… a US simulation model predicted 51.2M measles cases over a 25-year period, 9.9M rubella cases, 4.3M poliomyelitis cases, 197 diphtheria cases, 10.3M hospitalizations, and 159,200 deaths'<a href="https://t.co/kSDWqTRvhb">https://t.co/kSDWqTRvhb</a>
&mdash; Scott Gottlieb, MD &#x1f1fa;&#x1f1f8; (@ScottGottliebMD) <a href="https://twitter.com/ScottGottliebMD/status/1929201297674088748?ref_src=twsrc%5Etfw">June 1, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: The Health and Human Services Secretary (HHS), Robert F. Kennedy Jr, has come under increasing scrutiny for spreading vaccine misinformation. 
Last week, a senior vaccine official at the FDA, Peter Marks, resigned <a href="https://www.benzinga.com/markets/25/03/44550801/rfk-jr-spreading-misinformation-and-lies-fdas-top-vaccine-official-walks-out-sparking-debate-on-safety-and-public-trust">from his position</a>, while accusing Kennedy of actions that were harmful to public health.
This also comes amid extensive <a href="https://www.benzinga.com/25/03/44514142/rfk-jr-to-announce-10000-job-cuts-shut-regional-agencies-in-a-major-health-department-overhaul-report">budget and job cuts</a> at the federal healthcare department, which includes the FDA, the National Institute of Health, and the Centers for Disease Control and Prevention, which could impair the ability of these agencies to perform their tasks effectively. 
See Also:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/macro-economic-events/25/06/45714416/former-treasury-secretary-larry-summers-warns-the-dollar-is-starting-to-trade-like-a-latin-american-currency-greenback-going-from-safe-haven-to-risk-asset">Former Treasury Secretary Larry Summers Warns The Dollar Is Starting To Trade Like A Latin American Currency — Greenback Going From Safe Haven To Risk Asset?</a></li>
</ul>
Photo courtesy: Shutterstock

Health Care

51.2 Million Measles Cases, 159,200 Deaths: New Study Warns Of Surge In Preventable Diseases Amid Growing Vaccine Skepticism

<ul>
<li>BRUKINSA plus venetoclax demonstrated high response rates and a favorable safety profile across CLL patient types in SEQUOIA Arm D, including those with high-risk del(17p) mutational status</li>
<li>At 5-year follow-up of SEQUOIA Arm C, BRUKINSA monotherapy showed sustained OS and PFS benefit in hard-to-treat del(17p) CLL patients versus historical data</li>
</ul>

Reported Saturday, BeOne's SEQUOIA Trial Shows BRUKINSA Plus Venetoclax Yields Deep, Durable Responses Across CLL Risk Groups Including del(17p) And TP53

Macro Economic Events

Econ #s

Economics

U.K. Manufacturing Purchasing Managers Index For May 46.4 Vs. 45.1 Est.; 45.4 Prior

Broad Arrow Auctions, a Hagerty (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HGTY#NYSE">HGTY</a>) company, is delighted to announce the addition of a new event on its global auction calendar—The Zoute Concours Auction, held in collaboration with Zoute Grand Prix Car Week (8-12 October 2025) in Belgium. Set for Friday, 10 October on the grounds of the beautiful Approach Golf in Knokke-Heist, a stone's throw from the beach, the single-day auction will present approximately 70 exceptional collector cars across a wide variety of categories, marques, and price points.

HGTY

Hagerty's Broad Arrow Adds Belgium Auction Featuring 70 Classic Cars at Zoute Grand Prix

<h3>Companies Reporting Before The Bell</h3>
• The Campbell's (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CPB#NASDAQ">CPB</a>) is expected to report quarterly earnings at $0.66 per share on revenue of $2.43 billion. 
• Science Applications Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIC#NASDAQ">SAIC</a>) is estimated to report quarterly earnings at $2.12 per share on revenue of $1.87 billion. 
<h3>Companies Reporting After The Bell</h3>
• Credo Technology Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRDO#NASDAQ">CRDO</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $159.59 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

CRDO

SAIC

Earnings Scheduled For June 2, 2025

U.S. President Donald Trump has announced the withdrawal of Jared Isaacman's nomination for the NASA administrator job due to Isaacman's "prior associations."
What Happened: "After a thorough review of prior associations, I am hereby withdrawing the nomination of Jared Isaacman to head NASA," Trump said in a post on Truth Social on Saturday.
The president then went on to say that he would announce a new nominee soon, who would be more "Mission aligned, and put America First in Space," Trump said.
<figure class="wp-block-image aligncenter size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="361" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg" alt="" class="wp-image-934652" style="width:484px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-1024x361.jpg 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-300x106.jpg 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social-768x271.jpg 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/06/02030720/Trump-truth-social.jpg 1211w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
source: Truth Social
Isaacman has donated to the Democratic Party in prior elections, as the <a href="https://www.opensecrets.org/donor-lookup/results?name=Jared+Isaacman&amp;order=desc&amp;sort=D">data</a> from the non-profit organization OpenSecrets showcases the Shift4 CEO donating to a candidate from the party.&nbsp;
Why It Matters: The news comes in just days after billionaire Elon Musk's exit from the Trump administration's DOGE, or Department of Government Efficiency. The president also hosted <a href="https://www.benzinga.com/news/25/05/45707423/trump-says-he-is-having-elon-musk-over-at-the-white-house-tomorrow-for-a-press-conference-as-billion">Musk at the White House</a>.
Isaacman's withdrawal by Trump casts uncertainty over NASA's commitment to Mars exploration, something that Isaacman had <a href="https://www.benzinga.com/general/space/25/04/44730104/trumps-nasa-chief-pick-isaacman-tells-senate-we-will-prioritize-sending-american-astronauts-to-mars">doubled down on</a> in the past and is a major target for Musk's SpaceX.
SpaceX recently held a test launch for its Starship rocket from a launch site in Texas. However, the launch failed as the <a href="https://www.benzinga.com/general/space/25/05/45636692/elon-musks-mars-ambitions-face-new-setback-as-spacex-starship-test-flight-fails">rocket spun out of control </a>30 minutes into the mission after it was launched in suborbital space.
Check out more of Benzinga's Future Of Mobility coverage by<a href="https://www.benzinga.com/topic/mobility"> following this link.</a>
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/tech/25/05/45637814/elon-musk-admits-he-spent-too-much-time-on-politics-after-tesla-sales-decline-in-multiple-regions">Elon Musk Admits He Spent &#8216;Too Much Time&#8217; On Politics After Tesla Sales Decline In Multiple Regions</a></li>
</ul>
Photo courtesy: Pandora Pictures / Shutterstock.com

SPACE

Donald Trump Withdraws Jared Isaacman's Nomination For NASA Administrator, Says New Nominee Would 'Put America First in Space'

<ul>
<li>Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median progression-free survival when compared to fulvestrant in second line-plus patients with an estrogen receptor 1 mutation</li>
<li>Vepdegestrant was generally well tolerated, with few discontinuations and low rates of gastrointestinal-related adverse events</li>
<li>Vepdegestrant is the first and only PROteolysis TArgeting Chimera (PROTAC) evaluated in a Phase 3 clinical trial and the first to show benefit in patients with breast cancer</li>
<li>Data to be featured in a late-breaking oral presentation at ASCO and simultaneously published in the New England Journal of Medicine</li>
</ul>

ARVN

Reported Saturday, Arvinas and Pfizer's Vepdegestrant Demonstrates Statistically Significant 2.9-Month PFS Benefit Over Fulvestrant In ESR1-Mutant Second-Line Advanced Breast Cancer

Comments

NexPoint Residential

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL